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Abstract: Medulloblastoma is the most common malignant paediatric brain tumour and current
therapies often leave patients with severe neurological disabilities. Four major molecular groups
of medulloblastoma have been identified (Wnt, Shh, Group 3 and Group 4), which include additional,
recently defined subgroups with different prognosis and genetic characteristics. Lactate dehydrogenase
A (LDHA) is a key enzyme in the aerobic glycolysis pathway, an abnormal metabolic pathway
commonly observed in cancers, associated with tumour progression and metastasis. Studies indicate
MBs have a glycolytic phenotype; however, LDHA has not yet been explored as a therapeutic target
for medulloblastoma. LDHA expression was examined in medulloblastoma subgroups and cell lines.
The effects of LDHA inhibition by oxamate or LDHA siRNA on medulloblastoma cell line metabolism,
migration and proliferation were examined. LDHA was significantly overexpressed in Group 3 and
Wnt MBs compared to non-neoplastic cerebellum. Furthermore, we found that oxamate significantly
attenuated glycolysis, proliferation and motility in medulloblastoma cell lines, but LDHA siRNA did not.
We established that aerobic glycolysis is a potential therapeutic target for medulloblastoma, but broader
LDH inhibition (LDHA, B, and C) may be more appropriate than LDHA inhibition alone.
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1. Introduction
Brain and other central nervous system (CNS) tumours are the second largest cause of cancer-related
deaths in children, after leukaemia. Medulloblastomas (MBs) account for 20% of paediatric brain tumours,
making them the most common type of solid, malignant childhood brain tumour [1]. MB manifests
in the cerebellum and has a tendency to spread to the spinal cord. Four main subgroups of MB have
been identified and are now recognised by the World Health Organisation (WHO): as Wnt-activated,
Shh-activated TP53 wild-type, Shh-activated TP53 mutant and non-Wnt/non-Shh, the latter of which has
been subdivided into “Group 3” and “Group 4” [2,3]. Recent studies reveal even further divisions [4].
Each group has disparate features including demographics, clinical outcomes, characteristic genetic
abnormalities and rates of metastasis. Although the current five-year event-free survival is >80% for
low-risk children, and 60–70% for high-risk children [5], the quality of life of individuals after treatment is
often significantly reduced.
Regardless of oxygen availability, cancer cells commonly use aerobic glycolysis for ATP
production; this is known as the Warburg effect [6]. Pyruvate is diverted away from the mitochondria,
where it normally undergoes oxidative phosphorylation (OXPHOS) to generate ATP. Instead, it is
converted to lactate by LDHA and nicotinamide adenine dinucleotide (NAD+) is regenerated from
(NAD)H in the process [7]. NAD+ is required by glyceraldehyde 3-phosphate dehydrogenase to
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maintain glycolysis and ATP production. This reaction also occurs occasionally in some specialised
non-neoplastic cells during rapid proliferation and other non-neoplastic cells when oxygen is
unavailable. Nevertheless, as this is the preferential method of ATP production used by cancer
cells, it is an attractive target for cancer therapies. We previously reviewed the regulation and function
of LDHA and its therapeutic potential in brain tumours [8].
Mouse models have shown that during normal development of the cerebellum, cerebellar
granule neural precursors (CGNPs) are stimulated by Shh to undergo aerobic glycolysis. Shh and
phosphoinositide 3-kinase signalling has been shown to stimulate aerobic glycolysis in CGNPs in a
hexokinase-2 (HK2)-dependent manner [9]. Furthermore, inhibition of aerobic glycolysis by deleting
HK2 in Shh MB mouse models reduced MB malignancy by promoting differentiation and reducing
proliferation [9]. Shh MBs also exhibit elevated lipid synthesis implicated in aerobic glycolysis [10].
Using magnetic resonance spectroscopy and 18fluorodeoxyglucose positron emission tomography,
MBs in patients have been shown to have a glycolytic metabolic phenotype and a recent study has
shown elevated lactate levels were associated with a Group 3/4 subgroup [11,12]. MBs also have
elevated expression of monocarboxylate transporter 1 (MCT1), which transports lactate and pyruvate
across the plasma membrane, also indicating a glycolytic phenotype [13]. Moreover MCT1 is inhibited
by miR-124, which is commonly downregulated in MB, and ectopic expression of miR-124 has been
shown to inhibit MB proliferation by blocking cell cycle progression at G1.
Cellular metabolism can be influenced by many pathways, including several implicated in
MB. The Wnt signalling network has been shown to increase glycolysis and decrease oxidative
phosphorylation [14,15]. C-Myc, which is overexpressed in Group 3 MB and activated downstream of
Wnt signalling pathways, is also known to promote glycolysis in many cancers [2,16] and upregulates
LDHA expression [17]. Although MB is made up of four distinct subgroups, together these studies
indicate that aerobic glycolysis is a common feature of most if not all MBs.
LDHA has not yet been explored as a therapeutic target for MB. We used oxamate, a structural
analogue of pyruvate, which competes with pyruvate to inhibit LDHA activity (not expression) [18] and
LDHA siRNA to investigate the therapeutic potential of targeting LDHA in MB. We hypothesised that
LDHA inhibition would result in a decrease in lactate concentrations and a change from a glycolytic
to an oxidative phosphorylation metabolic phenotype, leading to decreased medulloblastoma,
proliferation and motility.
2. Materials and Methods
Cell culture: Human MB cell lines UW402, Res256 (Dr. John Silber, University of Washington,
Seattle, WA, USA) were cultured in Dulbecco’s Modified Eagle’s medium (Gibco, Paisley, UK), 10% FBS.
Human MB cell line DAOY (ATCC, London, UK) was cultured in Eagle’s minimum essential medium
(ATCC), 10% FBS. Cells were maintained in a 37 ◦C, 95% air, 5% CO2 in a humidified incubator
(NUAIRE, Caerphilly, UK). Cells were routinely screened for mycoplasma using the MycoAlert™
mycoplasma detection kit (Lonza, London, UK).
Analysis of patient data: Gene expression datasets were obtained and analysed using the R2
genomics and visualisation platform (http://r2.amc.nl) [19] LDHA expression was analysed from a
selection of CNS tissues available from the Normal Various-Roth-504–MAS5.0–u133p2 dataset and in
MBs using the Tumor Medulloblastoma-Gilbertson-76–MAS5.0–u133p2 dataset.
Western blot: Cells were lysed with M-PER® (Thermo Scientific, Basingstoke, UK) and Halt™
protease and phosphatase inhibitor cocktail (Thermo Scientific, Basingstoke, UK, 1:100). 50 µg of
protein was separated by SDS-PAGE in Tris-Glycine 4–20% gels (Thermo Scientific, Basingstoke UK)
and transferred onto Immun-Blot® PVDF membrane (Bio-Rad, Oxford, UK). Blots were incubated
overnight at 4 ◦C in 5% milk blocking buffer containing LDHA (Novus Biologicals, Oxford, UK) or
Cyclophilin A antibody (Abcam, Cambridge, UK). The blots were washed in TBST and incubated
with Goat anti-rabbit IgG horseradish peroxidase antibody (Promega, Southampton, UK) for 1 h
at room temp. The blots were incubated with Luminata™ Forte Western HRP Substrate (Merck
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Millipore, Watford, UK) and imaged using the G-Box chemiluminescent imaging system (Syngene,
Cambridge, UK). Semi-quantitative downstream analysis of protein expression was performed using
Image J software.
Flow Cytometry: Cells were harvested and centrifuged at 300 RCF at 4 ◦C, the supernatant removed
and pellet washed in PBS (Gibco, Poole, UK). The pellet was re-suspended in of BD cytofix/cytoperm™
fixation and permeabilisation solution (BD Biosciences, Oxford, UK), and incubated for 20 min at 4 ◦C
in the dark. The cells were washed with wash buffer (PBS with 0.2% saponin, and 1% goat serum) and
re-suspended with LDHA antibody (Novus Biologicals) and incubated for 30 min at 4 ◦C. Cells were
washed with wash buffer and re-suspended with goat anti-rabbit IgG Alexa fluor 488 (Life Technologies,
Warrington, UK), and incubated for 15 min at 4 ◦C. Cells were washed with wash buffer and re-suspended
in staining buffer (PBS with 1% goat serum and 0.09% w/v sodium azide pH to 7.4–7.6) and 20,000 events
from each sample analysed using a BD FACSCalibur™. Acquisition and analysis were performed using
CellQuestPro software to determine cell line expression of antigen.
Oxamate: Cells were seeded and left to adhere overnight before treatment with oxamate (0 h).
Oxamate (Sigma Aldrich, Poole, UK) stock was prepared at 0.5 M concentrations in dH2O and filtered,
using a Millex®-GP 22µm filter unit (Merck Millipore, Watford, UK).
Small interfering RNA (siRNA) knockdown: Stock LDHA Silencer® select pre-designed siRNA
(Ambion, Basingstoke, UK, 4392420) and Silencer® select Negative control #1 siRNA (Ambion, UK)
in nuclease-free water (Ambion, UK) were diluted in Opti-MEM (Gibco, UK). The siRNA stock was
mixed with jetPRIME® buffer and jetPRIME® reagent (Polyplus transfection®, Source Bioscience Life
Sciences, Nottingham, UK) according to the manufacturer’s instructions. 15 nmol siRNA was added
to 70,000 cells in 12-well plates and the media changed after 24 h. LDHA knockdown was verified by
Western blots parallel to every functional siRNA experiment.
Lactate assay: Lactate concentrations were measured using a lactate assay kit (MAK064, Sigma
Aldrich, UK) according to the manufacturer’s instructions. Cells were lysed and protein concentration
determined by BCA. 20 µL of lysates were analysed at 570 nm using POLARstar OPTIMA plate reader
(BMG Labtech, Aylesbury, UK).
Glycolysis stress test and Mito stress test: Glycolysis and mitochondrial activity was measured
using the Seahorse Bioanalyser 96XF with Seahorse Bioanalyser Glycolysis stress test kit and Mito stress
test kit according to the manufacturer’s instructions respectively. Cells were treated with oxamate 24 h
prior to analysis and data analysis was conducted using Wave software.
Trypan blue exclusion assay: Cells were harvested from six-well plates, transferred into Vi-Cell
cups and counted using the Vi-Cell® (BeckMan Coulter, High Wycombe, UK) automated trypan blue
dye exclusion assay. Seeding density was optimised for each cell line to ensure that no more than 85%
confluence was achieved by the 72 h time point in the control wells.
Cell cycle analysis: Cells were harvested from six-well plates and centrifuged at 500 RCF at
room temperature, the supernatant discarded then washed and re-suspended in PBS (Gibco, UK).
The cells were fixed with cold 70% ethanol and stored at 4 ◦C for seven days. The ethanol-suspended
cells were centrifuged at 800 RCF at 4 ◦C and the supernatant removed. The cells were washed with
PBS and re-suspended in Chemometec Solution 3 (1 µg/mL DAPI, 0.1% triton x-100 in PBS). 10 µL
of each sample was loaded into a chamber of a NC-Slide A8™ and >10,000 cells analysed using the
NucleoCounter® NC-3000.
Live cell imaging: A scratch was made through a monolayer of cells in a 24-well plate using a
pipette tip. The media was removed and replaced with 500 µL of appropriate media (with/without
oxamate) and secured into a Ziess Axiovert 200 M microscope stage enclosed in a temperature
(tempcontrol 37-2 digital, Meyer instruments, Houston, TX, USA), CO2 and oxygen (Bold line, Okolab,
Indigo Scientific, Baldock, UK) controlled incubator set to 37 ◦C, 95% air, 5% CO2. Images were taken
every 30 minutes using Volocity® acquisition software (PerkinElmer, Chiltern, UK). The area of the
gap was measured using T Scratch software developed by the Koumoutsakos group (CSE Lab, Zürich,
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Switzerland), at ETH Zürich [20]. 10 cells from the edge of each scratch were tracked manually for the
first 24 h using Volocity® analysis software (PerkinElmer, Chiltern, UK).
Statistics: All experiments were completed together and independently in triplicate. All statistical
analysis was carried out using GraphPad Prism 6 software (6.0, GraphPad Software, San Diego, CA,
USA). p-values less than 0.05 were considered significant. t tests were used to analyse the WB and FC
data. Ordinary one-way ANOVA was used to analyse the R2 database genomic data and to analyse
24 h of cell tracking data. Two-way ANOVA was used for all other experiments.
3. Results
3.1. LDHA Expression in MB
Analyses of LDHA mRNA levels were conducted using publicly available datasets (Figure 1A,B).
Non-neoplastic cerebellum expressed low levels of LDHA compared to other non-neoplastic CNS
tissue, and significantly less than the midbrain (p ≤ 0.01), parietal lobe and frontal lobe (p ≤ 0.05).
The dataset used does not specify the age range of the patient samples; however, this finding correlates
with previous studies that used magnetic resonance imaging and positron emission tomography scans
in neurologically normal young adults. One study found that aerobic glycolysis was significantly
elevated in the medial and lateral parietal and prefrontal cortices; however, the cerebellum had
significantly lower levels of aerobic glycolysis than the rest of the brain [21]. There are limited
data available on the expression of LDHA in the human cerebellum during prenatal and postnatal
neurogenesis, but it may correlate with other genes associated with glycolysis that have been
investigated. Goyal et al. [22] found that during the first few months of gestation, an increase in
the expression of 116 glycolytic genes occurs in parallel across the brain. Interestingly, at mid-gestation
the expression of these 116 glycolytic genes falls sharply in the cerebellum but stabilizes in the
diencephalon, and continues to increase in the striatum and cerebral cortex.
Figure 1. Cont.
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Figure 1. LDHA expression in MB and non-neoplastic tissue and cell lines. (A,B) LDHA expression
in CNS tissues from data extracted using the R2 data base. The number of samples per tissue is
stated in parentheses. Graphs show box plots (highest value, lowest value, upper quartile, lower
quartile, interquartile range and median). (A) LDHA expression in non-neoplastic CNS tissues. LDHA
expression in cerebellum and CNS were compared to every other CNS tissue; (B) LDHA expression in
a range of non-neoplastic CNS tissues and MB subgroups. LDHA expression was compared between
MB subgroups and compared to normal cerebellum and spinal cord; (C) Representative Western blot
of lysates from MB cell lines UW402, Res256 and DAOY. 50µg of protein was loaded into each well and
the blot was probed for LDHA (37 kDa) and cyclophillin A (18 kDa) as a loading control; (D–I) Flow
cytometry analysis of LDHA expression in MB cell lines; solid grey = negative control, light grey
line = LDHA expression (D) UW402; (E) DAOY; (F) and Res256; (G) Percentage of cell populations
expressing LDHA. (H) Mean LDHA expression (fluorescence intensity). Graphs show mean with SEM.
Not significant p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
We also examined the differences in LDHA expression between the four MB subgroups and found
that LDHA expression was as follows; Group 3 (N = 16) > Wnt (N = 8) > Group 4 (N = 39) > Shh (N = 10)
Group 3 and Wnt MBs also expressed significantly more LDHA than non-neoplastic cerebellum (N = 9)
and spinal cord tissue (N = 9) (p ≤ 0.0001 and p ≤ 0.05 respectively). Considering that previous studies
have shown that Shh promotes aerobic glycolysis [9,23] it was surprising that Shh MBs had lower mean
LDHA expression than non-neoplastic cerebellum and spinal cord tissue. As C-myc is a transcription
factor for LDHA [17], it is not surprising that Group 3 and Wnt MBs express significantly higher levels
of LDHA than non-neoplastic cerebellum and spinal cord, as Group 3 is known to overexpress c-Myc
and c-Myc is also a downstream target of the Wnt signalling pathway. Group 3 is the most metastatic
subgroup of MB and carries the poorest prognosis; these features are also commonly associated
with LDHA and lactate concentrations in other tumours [24]. Group 3 MBs expressed significantly
higher levels of LDHA than all the other MB subgroups indicating that LDHA could be a promising
therapeutic target specifically against Group 3 MBs. LDHA was also abundantly expressed in MB cell
lines (Figure 1C–H).
3.2. Oxamate Attenuates MB Proliferation
In order to reveal the potential therapeutic benefits of targeting LDHA in MB, LDHA activity (not
expression) was inhibited by oxamate and the downstream effects on MB proliferation, metabolism and
motility examined.
As shown by previous studies in other cell lines [25–27], we found that oxamate significantly
attenuated the number of viable MB cells in a time- and concentration-dependent manner, the Res256
cell line was the most sensitive and DAOY the least sensitive (Figure 2A–C). By inhibiting LDHA and
aerobic glycolysis, oxamate could reduce the rate at which ATP can be generated and therefore the rate
at which MB cells can proliferate. It is possible that because Res256 had a lower expression of LDHA,
lower concentrations of oxamate were able to have a more significant effect. Further investigations
indicated that oxamate treatments significantly reduced the percentage of MB cells in G0/G1 and
significantly increased the percentage of MB cells in G2/M in a concentration dependent manner
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(Figure 2D–F). Res256 and UW402 cells were similarly sensitive whereas DAOY cells were somewhat
less sensitive. Together, these experiments suggest that oxamate caused a G2/M cell cycle arrest in MB
cells, as reported previously in nasopharyngeal carcinoma cells [25]. However, further investigations
are required to determine why DAOY cells are less affected by oxamate, one possibility is that they are
better adapted to switching from aerobic glycolysis to OXPHOS.
Figure 2. Effects of oxamate on MB proliferation and motility. MB cell lines were grown in the presence
of 0 mM, 25 mM, 50 mM or 75 mM oxamate. (A–C) Number of viable cells 0–72 h after treatment
counted by Vi-Cell automated cell counter (A) UW402, (B) DAOY and (C) Res256; (D–F) Mean
percentage of cells in G0, S and G2/M phases of the cell cycle 48 h after treatment (D) UW402,
(E) DAOY, (F) Res256; (G–I) Average velocity (µm/second) of individual (G) UW402, (H) DAOY and
(I) Res256 cells over 24 h. Cells were imaged every 30 minutes and tracked manually using Volocity
software. Graphs show mean with SEM. Oxamate treated samples were compared to the untreated
control at each time point, not significant p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
3.3. Oxamate Inhibits MB Cell Speed of Migration
Approximately 30% of MBs are metastatic at diagnosis and are associated with a poorer
prognosis [28] and previous studies in other cancers have shown that lactate is a prognostic factor for
metastasis [24,29,30]. Using live cell imaging, we found that oxamate significantly inhibited MB cell
migration (p ≤ 0.0001) (Figure 2G–I). Together these studies show that by inhibiting LDHA activity
and lactate production, MB motility is significantly reduced, a finding that could be of great benefit
when developing therapies to reduce the devastatingly metastatic nature of the disease.
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3.4. Oxamate Inhibits MB Aerobic Glycolysis and Promotes OXPHOS
The abundant expression of LDHA and lactate in the MB cell lines suggests they, like most cancers,
have a glycolytic phenotype [6]. As shown previously in other cell lines [25–27], we found that oxamate
significantly inhibited lactate concentrations in every cell line (Figure 3A–C), indicating successful
inhibition of LDHA activity, lactate production and the glycolytic phenotype.
Figure 3. Effects of oxamate on MB metabolism. MB cell lines were grown in the presence of 0
mM, 25 mM, 50 mM or 75 mM oxamate. (A–C) Lactate concentrations of lysates prepared from (A)
UW402, (B) DAOY, and (C) Res256 cells treated for 24–72 h. Lactate concentrations were normalised
to the protein concentrations of each sample. (D) ECAR (mpH/min) of UW402 cells treated for 24
h. Glycolysis, glycolytic capacity and glycolytic reserve calculated from changes in ECAR with the
addition of glucose, oligomycin and 2-DG. (E) Oxygen consumption rate (pmoles/min) of UW402 cells
treated for 24 h. Basal respiration, ATP production and maximal respiration calculated from changes in
OCR with the addition of oligomycin, FCCP, rotenone and antimycin A. Oxamate-treated samples were
compared to the untreated control at each time point. Graphs show mean with SEM, not significant
p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
Although all three MB cell lines showed high levels of LDHA expression, the UW402 MB cell
line was chosen for examination in more detail as it is known to have isochromosome 17q, which is
typical of Group 3 and Group 4 MBs, the most metastatic MBs that carry the poorest prognosis [31].
DAOY cells have been molecularly subgrouped as Shh MB [32] and Res256 cells have not been
subgrouped, to our knowledge. After 24 h all oxamate treatments significantly reduced UW402 cell
glycolysis, glycolytic capacity and glycolytic reserve (p≤ 0.0001) (Figure 3D). Furthermore, all oxamate
treatments caused a significant increase in UW402 cell basal respiration, ATP production and maximal
respiration (p ≤ 0.0001), suggesting an increase in OXPHOS metabolism (Figure 3E). Together these
studies confirm that oxamate significantly altered MB metabolism, reduced LDHA activity, aerobic
glycolysis and lactate production, and increased OXPHOS in UW402 cells.
3.5. Oxamate and LDHA as a Therapeutic Target for MB
We have shown that oxamate significantly inhibits MB lactate production, aerobic glycolysis,
proliferation and motility and also upregulates OXPHOS. Although the data presented here, and by
others, using oxamate and LDHA to target cancer are promising, unfortunately the concentration of
oxamate required to have significant effects is far too high to be considered for clinical use. As more
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suitable LDHA targeted therapies are in development, we wanted to corroborate our findings with
LDHA-targeted siRNA (Figure 4).
Figure 4. Effects of LDHA siRNA on UW402. UW402 cells were untreated, treated with vehicle control
(jet prime transfection reagent), LDHA siRNA and jet prime transfection reagent, or control siRNA and
jet prime transfection reagent. (A,B) Western blot of lysates prepared from UW402 cells 72–96 h after
transfection. 25µg of protein was loaded into each well and the blot was probed for LDHA (37 kDa) and
cyclophillin A (18 kDa) as a loading control. (A) Western blot bands; (B) Semiquantitative analysis of
LDHA expression using image J software. LDHA expression was normalised to Cyclophilin expression.
LDHA expression is represented as a fold change from control siRNA LDHA expression at each time
point; (C) Lactate concentrations of lysates prepared from UW402 cells 72–96 h after transfection. Lactate
concentrations were normalised to the protein concentrations of each sample. Graphs show mean with
SEM. All samples were compared to each other at each time point, **** p ≤ 0.0001.
3.6. LDHA siRNA Does Not Inhibit MB Viability, Cell Migration or Metabolism
We found that >80% knockdown of LDHA expression did not have any significant downstream
effects on MB cell metabolism, growth or motility (data not shown). However, previous studies in
other cell lines that had also not achieved a 100% knockdown of LDHA found it caused a significant
reduction in tumour cell migration, growth and maintenance, similar to the results we saw with
oxamate [33–35].
It is possible that as LDHA was not completely knocked down in the MB cells, the remaining
LDHA was able to compensate for the loss. Another possibility is that other LDH family members
were able to compensate when LDHA was knocked down. LDHA and LDHB can form homo- or
heterotetramers that have identical active site regions [8,36], so it is likely that oxamate has inhibitory
effects on all five LDH tetramers and that is why it was more effective than LDHA siRNA.
Analysis of LDHB gene expression using the R2 genomics and visualisation platform revealed
that the mean expression of LDHB within the MB subgroups was as follows; Shh > Wnt > Group 3 >
Group 4 (Figure 5A). Shh MBs had significantly higher LDHB expression than the other MB subgroups.
As previous studies have shown Shh MBs have a glycolytic phenotype and we found that they express
the least amount of LDHA out of the MB subgroups, it is possible that LDHB is undertaking the role
normally expected of LDHA. There was no significant difference in LDHC expression between the MB
subgroups (Figure 5B). Furthermore, the Wnt, Shh and Group 3 subgroups expressed significantly less
LDHC than the cerebellum.
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Figure 5. Effects of LDHA siRNA on UW402 LDHB and LDHC expression. (A,B) Expression of
(A) LDHB and (B) LDHC in MB subgroups, non-neoplastic cerebellum, spinal cord and foetal brain.
The number of samples per tissue is stated in brackets. Graphs show box plots (highest value, lowest
value, upper quartile, lower quartile, interquartile range and median). Not significant p > 0.05,
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001; (C,D) Western blots of lysates prepared from
UW402 cells treated with jet prime transfection reagent (vehicle control), UW402 cells treated with
LDHA siRNA and jet prime transfection reagent and UW402 cells treated with control siRNA and jet
prime transfection reagent 72–96 h after transfection. 25 µg of protein was loaded into each well and the
blot was probed for C) LDHB or D) LDHC (37 kDa) and cyclophillin A (18 kDa) as a loading control.
Previous LDHA knockdown studies that show tumour attenuation have not verified the
knockdown status of other LDH family members [33–35,37]. In our study we found that lysates
treated with LDHA siRNA also had marked LDHC knockdown but LDHB expression remained
relatively unchanged (Figure 5C,D). Therefore, our results suggest that the attenuation of MB aerobic
glycolysis, motility, viability, proliferation and lactate production may require LDHB inhibition as well
as LDHA inhibition and possibly LDHC inhibition. However, further extensive studies based on the
foundation of these results are necessary to confirm this hypothesis.
4. Discussion
The high glucose requirement of MB cells and other tumours makes them vulnerable to therapies
that target aerobic glycolysis. We have shown that LDHA was significantly elevated in Group 3 and
Wnt MBs and LDHB was significantly upregulated in Shh MBs compared to non-neoplastic cerebellar
tissue. We found that oxamate significantly attenuates MB aerobic glycolysis, proliferation and motility
however, unlike studies in other tumours; our LDHA knockdown studies did not result in the same
functional observations. In our study, we also explored the impact of LDHA siRNA on the other LDH
family members and documented that LDHA siRNA knocked down LDHC considerably as well as
LDHA, but not LDHB. One explanation for the disparity is that other LDH family members may have
been attenuated in other experiments as well but the impact of LDHA knockdown on all LDH family
members is not routinely assessed. In addition, our data were obtained from using established MB cell
lines in vitro; therefore, additional experiments in more complex models that better represent in vivo
micro-environments are needed.
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5. Conclusions
Further investigations will be critical as LDHA may prove to be an inadequate target for MB
and a broader LDH family inhibitor that also targets LDHB may be more appropriate to exploit this
weakness whilst limiting damage to non-neoplastic cells. In future studies it would be of interest to
explore the knockdown of LDHA, LDHB and LDHC, as well as the use of broad LDH inhibitors in MB
mouse models [38,39].
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